Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00915876 · ClinicalTrials.gov registry record · NA
Vascular Reactivity in Chronic Kidney Disease (CKD) Patients Receiving Paricalcitol Versus Placebo
A NA study of Chronic Kidney Disease, sponsored by Amy Barton Pai.
- Completed
- Registry status
- NA
- Development phase
- 41
- Enrollment target
- 1
- Study location
NCT00915876: Completed NA study of Chronic Kidney Disease, sponsored by Amy Barton Pai.
NCT00915876 is a NA study of Chronic Kidney Disease that has completed, run by Amy Barton Pai. The registered enrollment target is 41 participants, below the 3,206-participant average among 101 other Chronic Kidney Disease trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00915876, a NA study of Chronic Kidney Disease, has completed, sponsored by Amy Barton Pai.
- COMPLETED
- Registry status
- NA
- Development phase
- 41 participants
- Enrollment target
- 1
- Study location
Study Summary
This research is studying how Vitamin D may affect blood vessels reaction to stress and blood levels of substances that may increase blockages in the blood vessels in chronic kidney disease (CKD) patients. Blood vessel health is worsened in CKD and some studies have shown that Vitamin D improves blood vessel health. The type of Vitamin D being used in this study (paricalcitol) is Food and Drug Administration (FDA) approved to treat high parathyroid hormone levels. The purpose of this study is to find out if paricalcitol has other benefits beyond its ability to lower parathyroid hormone levels such as improving the blood vessels reaction to stress and decreasing blood levels of substances that may increase blockages in the blood vessels.
Primary Outcome
Values of ICAM-1 (intracellular adhesion molecule) a measure of vascular reactivity, at three time points: baseline, day 28, and day 56
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Paricalcitol
Study Locations (1)
New York
- Albany Medical Center South Clinical Campus - Albany
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2009-03 |
| Est. Completion | 2011-03 |
| Phase | NA |
What the finished NCT00915876 record still lists
NCT00915876 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 41 participants, a relatively small participant target, below the 3,206-participant average among 101 other Chronic Kidney Disease trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Chronic Kidney Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00915876 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT00915876 about?
NCT00915876 is a clinical study titled "Vascular Reactivity in Chronic Kidney Disease (CKD) Patients Receiving Paricalcitol Versus Placebo". This research is studying how Vitamin D may affect blood vessels reaction to stress and blood levels of substances that may increase blockages in the blood vessels in chronic kidney disease (CKD) patients. Blood vessel health is worsened in CKD and some studies have shown that Vitamin D improves blo...
What is the current status of trial NCT00915876?
This trial is currently completed. It is a NA study. The enrollment target is 41 participants. The study started on 2009-03. Estimated completion is 2011-03.
What conditions does trial NCT00915876 study?
This clinical trial studies the following conditions: Chronic Kidney Disease.
What interventions are being tested in trial NCT00915876?
The interventions under investigation include: Placebo (DRUG), Paricalcitol (DRUG).
Who is sponsoring clinical trial NCT00915876?
This trial is sponsored by Amy Barton Pai, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00915876 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Kidney Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00915876's enrollment target sits among peer trials
41 76th of 101 higher than 25 of 101 other Chronic Kidney Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Kidney Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Pivotal Study of the Velocity™ pAVF System
RECRUITING · NA
-
Intensive Patient Referral and Education Program Prior to Renal Replacement Therapy
RECRUITING · NA
-
A Stakeholder-enhanced Intervention to Improve the Decisional Partnership of Chronic Kidney Disease Dyads (IMPART)
RECRUITING · NA
-
Transforming Hemodialysis-Related Vascular Access Education
RECRUITING · NA
-
Transcutaneous Auricular Vagus Nerve Stimulation Device in CKD Population
RECRUITING · NA
-
Staged Kidney Transplantation During Combined Heart/Kidney Transplantation
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03449238 · 41 participants · Phase 1
Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
- NCT03900793 · 41 participants · Phase 1
Losartan + Sunitinib in Treatment of Osteosarcoma
- NCT04082520 · 41 participants · Phase 2
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
- NCT04220190 · 41 participants · Phase 2
RAPA-501 Therapy for ALS
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia